Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Opus GeneticsIRD -7.07%20 3-Year Book Growth Rate is -53.70% as of Jun. 2026. GuruFocus rates IRD with a GF Score™ of 20/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,126 Biotechnology companies, Opus Genetics ranks worse than 88.72% on this metric.
During the past 12 months, Opus Genetics's average Book Value per Share Growth Rate was -153.80% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -53.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of Opus Genetics was -43.50% per year. The lowest was -53.70% per year. And the median was -48.60% per year.
Opus Genetics (NAS:IRD) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Opus Genetics 3-Year Book Growth Rate Related Terms
IRD vs OBIO, CYDY, YDES: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Opus Genetics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Opus Genetics's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -53.70% mean?
Opus Genetics (IRD) has a 3-Year Book Growth Rate of -53.70% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Opus Genetics and its competitors. According to the industry distribution chart, Opus Genetics ranks #999 out of 1126 companies in the Biotechnology industry, placing it in the top 88.7%.
Is Opus Genetics' 3-Year Book Growth Rate too high?
Opus Genetics' current 3-Year Book Growth Rate is -53.70%. Based on the distribution chart, Opus Genetics ranks #999 out of 1126 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Opus Genetics has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' 3-Year Book Growth Rate compare to OBIO and CYDY?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #999 out of 1126 companies for 3-Year Book Growth Rate. This places Opus Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Opus Genetics and its competitors. Opus Genetics's current 3-Year Book Growth Rate is -53.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $4.34 — trading 1450% above its estimated fair value. The current 3-Year Book Growth Rate is -53.70%. Opus Genetics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Opus Genetics (IRD), the current 3-Year Book Growth Rate is -53.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $4.34 is trading 1450% above its estimated GF Value™ of $0.28.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
3-Year Book Growth Rate: -53.70%
GF Value™: $0.28 vs. price of $4.34 (1450% above fair value)
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
20GF Score
Get the complete analysis for IRD
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 
